Get the Stockscreener App
25.71
1.08%
-0.28
Pre-market:
25.77
0.06
+0.23%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.71, with a volume of 36.34M.
It is down -1.08% in the last 24 hours and up +0.94% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.99
Open:
$25.935
24h Volume:
36.34M
Relative Volume:
0.96
Market Cap:
$145.71B
Revenue:
$63.63B
Net Income/Loss:
$8.03B
P/E Ratio:
18.23
EPS:
1.41
Net Cash Flow:
$9.84B
1W Performance:
-0.89%
1M Performance:
+0.94%
6M Performance:
-11.83%
1Y Performance:
-8.21%
1-Day Range:
$25.50
$25.97
1-Week Range:
$25.50
$27.24
52-Week Range:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.71 | 145.71B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
821.86 | 781.10B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.06 | 374.36B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.85 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
74.79 | 332.00B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
93.35 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Womens Health Market Is Booming Worldwide 2025-2032 | Pfizer - openPR
Pfizer sells park land to Portage for $1, deems property was 'surplus' - wwmtarc
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study - Benzinga
Is Pfizer Inc. (PFE) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Shareholders Will Be Pleased With The Quality of Pfizer's (NYSE:PFE) Earnings - Yahoo Finance
Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart
Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide - GlobeNewswire Inc.
Transthyretin Amyloid Cardiomyopathy Treatment Market Is Booming Worldwide 2025-2032: Pfizer Inc., - EIN News
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
A Snapshot Of What Pfizer's Doing With Teleoperated Robots - BioProcess Online
Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III - Citeline News & Insights
Sector Update: Health Care Stocks Lower in Late Afternoon Trading -March 11, 2025 at 04:05 pm EDT - Marketscreener.com
Looking At Pfizer's Recent Unusual Options Activity - Benzinga
Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant - Simply Wall St
Pfizer stock, Arvinas stock slip on breast cancer data (PFE:NYSE) - Seeking Alpha
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Benzinga
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients - Yahoo Finance
Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results - Reuters.com
mRNA Cancer Therapeutics Patent Landscape Report and - GlobeNewswire
Injectable Drugs Market Detailed In New Research Report 2025 | Pfizer Inc., Teva Pharmaceutical Industries - EIN News
Arvinas and Pfizer Announce Positive Phase 3 Trial Results - TipRanks
Pfizer: Undervalued Safe Haven In Risk-Off Market (NYSE:PFE) - Seeking Alpha
Pfizer's new drug data in breast cancer draws muted response - pharmaphorum
Pfizer (PFE) Breast Cancer Drug Vepdegestrant Posts Mixed Results in Key Trial - Bloomberg
Pfizer, Arvinas post mixed late-stage breast cancer data for closely watched PROTAC drug - PharmaLive
Pfizer: encouraging data in breast cancer -March 11, 2025 at 08:04 am EDT - Marketscreener.com
Pfizer's breast cancer drug Vepdegestrant posts mixed results in key trial - Business Standard
Atrial Fibrillation Market to Witness Remarkable Growth with Pfizer Inc., Boehringer Ingelheim GmbH - openPR
Migraine Therapeutic Market Is Booming Worldwide 2025-2032 | - openPR
Arvinas, Pfizer Report Positive Topline Data From Phase 3 VERITAC-2 Study - Nasdaq
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study -March 11, 2025 at 06:52 am EDT - Marketscreener.com
Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial - Marketscreener.com
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial - GlobeNewswire
First-Ever PROTAC Cancer Drug Hits Major Trial Milestone: What This Means - StockTitan
BioNTech posts $721M loss in 2024 due to low demand for COVID-19 vaccines - Yeni Şafak English
German Court Rules Pfizer, BioNTech Infringed Moderna's COVID-19 Vaccine Patent - Law.com
Moderna suffers setback in vaccine patent battle with Pfizer - The Business Journals
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations - Benzinga
U.S. Transthyretin Amyloidosis Market Projected To Witness Substantial Growth, 2025-2032:Alnylam - EIN News
Is Pfizer Inc. (PFE) the Most Undervalued US Stock to Buy According to Hedge Funds? - Insider Monkey
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold? - Nasdaq
BioNTech guides for worse-than-expected 2025 revenue decline -March 10, 2025 at 08:31 am EDT - Marketscreener.com
Pfizer lures former J&J exec to be its CIMO - The Pharma Letter
HSBC Adjusts Price Target on Pfizer to $35 From $38, Keeps Buy Rating -March 10, 2025 at 06:06 am EDT - Marketscreener.com
Cancer Biologics Market Projected To Witness Substantial Growth 2025-2032:Amgen Inc., Pfizer Inc., Sanofi S.A, - EIN News
Former Pfizer R&D chief Mikael Dolsten joins Immunai’s board of directors - The Jerusalem Post
Is Pfizer Inc. (PFE) The Best Cheap Dividend Stock To Buy Right Now? - Insider Monkey
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Pfizer Inc. (NYSE:PFE) - Defense World
Pfizer's Options: A Look at What the Big Money is Thinking - Benzinga
Covid Products Drove Pfizer's Fourth Quarter. Is It Now A Buy? - Investor's Business Daily
Zollinger Ellison Syndrome Market Research 2025: Novartis, GSK Plc, Bayer, Pfizer., and Bristol Myers Squibb Leading the $1.34 Billion LandscapeForecasts to 2034 - GlobeNewswire
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):